Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer
Tirzepatide decreased both mouse weight and tumor growth via effects on metabolic and immune pathways in the EC tumors that differed between obese and lean mice. This novel weight loss treatment deserves further evaluation as an innovative strategy in the management of EC.
Authors
- Victoria Bae‐Jump (ORCID: https://orcid.org/0000-0001-6778-0951)
- Stephen David Hursting (ORCID: https://orcid.org/0000-0003-3605-2833)
- Douglas S. Lee (ORCID: https://orcid.org/0000-0001-7078-745X)
- Xiaochang Shen
- Nikita Sinha (ORCID: https://orcid.org/0000-0003-4703-3937)
- Haomeng Zhang (ORCID: https://orcid.org/0000-0002-5599-0430)
- Boer Deng (ORCID: https://orcid.org/0000-0002-4833-9244)
- Angela D. Clontz (ORCID: https://orcid.org/0000-0003-0605-8329)
- Chunxiao Zhou (ORCID: https://orcid.org/0000-0002-1257-9537)
- Shuning Chen (ORCID: https://orcid.org/0000-0002-4628-370X)
- Jennifer Haag
- Wenchuan Sun
- Weimin Kong
- Catherine John
Institutions
- University of North Carolina at Chapel Hill (US)
- Strategic Insight (United States) (US)
- Beijing Obstetrics and Gynecology Hospital (CN)
Publication Details
- Journal
- Gynecologic Oncology
- Published
- 2024-10-10
- DOI
- https://doi.org/10.1016/j.ygyno.2024.10.004
- Citations
- 21
- Primary Topic
- Cancer Risks and Factors
- Type
- article
- Field-Weighted Citation Impact
- 5.93
Funders
- National Institutes of Health
- University of North Carolina at Chapel Hill
- National Cancer Institute